Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Victor Tapson

Showing results (31-40 of 46) with videos related to

Pageof 5
Sort By:
European Journal of Heart Failure|November 22, 2021
The impact of comorbidities on selexipag treatment effect in patients with pulmonary arterial hypertension: insights from the GRIPHON studyStephan Rosenkranz, Richard Channick, Kelly M Chin, et al.
Chest|August 31, 2020
Diagnosis and Treatment of Pulmonary Embolism During the Coronavirus Disease 2019 Pandemic: A Position Paper From the National PERT ConsortiumRachel P Rosovsky, Charles Grodzin, Richard Channick, et al.
Journal of the American College of Cardiology|June 25, 2003
Beraprost therapy for pulmonary arterial hypertensionRobyn J Barst, Michael McGoon, Vallerie McLaughlin, et al.
Annals of the American Thoracic Society|April 14, 2026
Biological Sex Differences in the US-CTEPH-RMeghan M Cirulis, William R Auger, Raymond L Benza, et al.
Critical Care Explorations|July 19, 2021
Performance Analysis of the National Early Warning Score and Modified Early Warning Score in the Adaptive COVID-19 Treatment Trial CohortChristopher J Colombo, Rhonda E Colombo, Ryan C Maves, et al.
Current Vascular Pharmacology|November 3, 2022
An Eight-year, Single-center Experience on Ultrasound Assisted Thrombolysis with Moderate-dose, Slow-infusion Regimen in Pulmonary EmbolismCihangir Kaymaz, Ozgur Yasar Akbal, Berhan Keskin, et al.
The New England Journal of Medicine|December 25, 2015
Selexipag for the Treatment of Pulmonary Arterial HypertensionOlivier Sitbon, Richard Channick, Kelly M Chin, et al.
Chest|November 19, 2019
Results of an Expert Consensus Survey on the Treatment of Pulmonary Arterial Hypertension With Oral Prostacyclin Pathway AgentsVallerie V McLaughlin, Richard Channick, Teresa De Marco, et al.
The European Respiratory Journal|May 29, 2024
Inhaled treprostinil in pulmonary hypertension associated with COPD: PERFECT study resultsSteven D Nathan, Rahul Argula, Maria G Trivieri, et al.
Chest|March 26, 2011
Predictive and associative models to identify hospitalized medical patients at risk for VTEAlex C Spyropoulos, Frederick A Anderson, Gordon FitzGerald, et al.
Pageof 5

Showing results (31-40 of 46) with videos related to

Sort By:
Pageof 5
European Journal of Heart Failure|November 22, 2021
The impact of comorbidities on selexipag treatment effect in patients with pulmonary arterial hypertension: insights from the GRIPHON studyStephan Rosenkranz, Richard Channick, Kelly M Chin, et al.
Chest|August 31, 2020
Diagnosis and Treatment of Pulmonary Embolism During the Coronavirus Disease 2019 Pandemic: A Position Paper From the National PERT ConsortiumRachel P Rosovsky, Charles Grodzin, Richard Channick, et al.
Journal of the American College of Cardiology|June 25, 2003
Beraprost therapy for pulmonary arterial hypertensionRobyn J Barst, Michael McGoon, Vallerie McLaughlin, et al.
Annals of the American Thoracic Society|April 14, 2026
Biological Sex Differences in the US-CTEPH-RMeghan M Cirulis, William R Auger, Raymond L Benza, et al.
Critical Care Explorations|July 19, 2021
Performance Analysis of the National Early Warning Score and Modified Early Warning Score in the Adaptive COVID-19 Treatment Trial CohortChristopher J Colombo, Rhonda E Colombo, Ryan C Maves, et al.
Current Vascular Pharmacology|November 3, 2022
An Eight-year, Single-center Experience on Ultrasound Assisted Thrombolysis with Moderate-dose, Slow-infusion Regimen in Pulmonary EmbolismCihangir Kaymaz, Ozgur Yasar Akbal, Berhan Keskin, et al.
The New England Journal of Medicine|December 25, 2015
Selexipag for the Treatment of Pulmonary Arterial HypertensionOlivier Sitbon, Richard Channick, Kelly M Chin, et al.
Chest|November 19, 2019
Results of an Expert Consensus Survey on the Treatment of Pulmonary Arterial Hypertension With Oral Prostacyclin Pathway AgentsVallerie V McLaughlin, Richard Channick, Teresa De Marco, et al.
The European Respiratory Journal|May 29, 2024
Inhaled treprostinil in pulmonary hypertension associated with COPD: PERFECT study resultsSteven D Nathan, Rahul Argula, Maria G Trivieri, et al.
Chest|March 26, 2011
Predictive and associative models to identify hospitalized medical patients at risk for VTEAlex C Spyropoulos, Frederick A Anderson, Gordon FitzGerald, et al.
Pageof 5